OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo
17 Maggio 2023 - 10:05PM
Business Wire
Suite of in silico tools leverages Company’s
Biological Intelligence™ and large proprietary multi-species
antibody databases to enhance the rapid identification of
therapeutic candidates with optimal profiles
OmniAb, Inc. (NASDAQ: OABI) announced the launch of
OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The
Essential Protein Engineering & Cell Therapy Summit. The
Company introduced elements of its OmniDeep platform at 1:10 p.m.
Eastern time today in a presentation by Bob Chen, Ph.D., OmniAb's
Senior Director, Systems Engineering.
OmniDeep is a suite of in silico tools for therapeutic discovery
and optimization that are woven throughout OmniAb’s various
technologies and capabilities. These tools include structural
modeling, molecular dynamics simulations, large multi-species
antibody databases, artificial intelligence, machine learning, deep
learning models and more. OmniDeep facilitates rapid identification
of candidates with the right affinity, specificity and
developability profiles intended to make drug development more
effective and efficient.
“OmniDeep enhances repertoire analysis and further streamlines
identification of the most promising therapeutic candidates for our
partners. This launch underscores our continued commitment to
invest in new technologies and to further innovate around our
technology stack,” said Matt Foehr, Chief Executive Officer of
OmniAb. “This expanded suite adds data-driven adaptable and
scalable insights that are valuable to quickly discover novel
therapeutics, and we are excited to offer these robust technologies
to current and future partners for their discovery programs.”
“OmniDeep arose from our long-standing computational biology and
in silico-based capabilities, which have been further developed and
applied toward the efficient mining of large and diverse antibody
repertoires generated through immunization of our proprietary
engineered animals,” stated Dr. Chen. “As we layer tools like
OmniDeep on the broad biological insights from our multiple species
of animals, we gain a deeper understanding of the vast antibody
repertoires they produce. We believe this knowledge allows us to
prioritize and optimize antibodies for performance and
developability profiles with the confidence that stems from
traceability back to a natural in vivo-evolved antibody.”
At the in vivo level, OmniDeep taps into Biological
Intelligence™, leveraging species-optimized transgenes and
structure-focused antigen design to create on-demand repertoires of
antibodies that are rich in leads directed toward a partner’s
targets of interest. At the in vitro level, OmniDeep’s multiplexed
high-throughput single cell phenotypic screening technologies are
designed to allow for rapid interrogation of millions of B cells
and the nearly immediate identification of functional antibodies.
The in silico technologies featured in OmniDeep enhance phenotypic
screens through efficient big data processing and provide the
ability to go a level deeper into the sequencing space where
additional potential lead candidates can exist.
OmniAb will be showcasing OmniDeep and its entire technology
stack at the PEGS Conference at booth #413. For more information
about OmniDeep and OmniAb’s various proprietary technologies,
please visit www.omniab.com or contact our business development
team at bd@omniab.com.
About OmniAb®
OmniAb’s discovery platform provides pharmaceutical industry
partners access to diverse antibody repertoires and high-throughput
screening technologies to enable discovery of next-generation
therapeutics. At the heart of the OmniAb platform is the Biological
Intelligence™ (BI) of our proprietary transgenic animals, including
OmniRat®, OmniChicken® and OmniMouse® that
have been genetically modified to generate antibodies with human
sequences to facilitate development of human therapeutic
candidates. OmniFlic® (transgenic rat) and OmniClic®
(transgenic chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur™
features unique structural attributes of cow antibodies for complex
targets. We believe the OmniAb animals comprise the most diverse
host systems available in the industry and they are optimally
leveraged through computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms to identify fully human antibodies with superior
performance and developability characteristics. These proprietary
technologies are joined with and leverage OmniDeep, which is a
suite of in silico tools for therapeutic discovery and optimization
that are woven throughout OmniAb’s various technologies and
capabilities. Additionally, an established core competency focused
on ion channels and transporters further differentiates OmniAb’s
technology and creates opportunities in many emerging target
classes. OmniAb antibodies have been leveraged across modalities,
including bispecific antibodies, antibody-drug conjugates and
others.
The OmniAb suite of technologies span from BI-powered repertoire
generation to cutting edge antibody discovery and optimization
offering a highly efficient and customizable end-to-end solution
for the growing discovery needs of the global pharmaceutical
industry.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. Words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or continue” and similar expressions, are intended to
identify forward-looking statements. The forward-looking statements
are based on our current beliefs and expectations and include, but
are not limited to: the ability of OmniDeep to make drug
development more effective and efficient or to identify functional
antibodies that can become therapeutic candidates; our expectations
regarding the application of, and the rate and degree of market
acceptance of, our technology platform and other technologies;
anticipated introduction of new technologies and innovations and
enhancement of our technology stack; continued innovation around,
and the expected performance of, our technologies; and the ability
to add new partners and programs. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: our future success is dependent on acceptance of our
technology platform and technologies by new and existing partners,
as well as on the eventual development, approval and
commercialization of products developed by our partners for which
we have no control over the development plan, regulatory strategy
or commercialization efforts; biopharmaceutical development is
inherently uncertain; risks arising from changes in technology; the
competitive environment in the life sciences and biotechnology
platform market; our failure to maintain, protect and defend our
intellectual property rights; difficulties with performance of
third parties we will rely on for our business; regulatory
developments in the United States and foreign countries; and other
risks described in our prior press releases and filings with the
SEC, including under the heading “Risk Factors” in the our annual
report on Form 10-K and any subsequent filings with the SEC. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and we
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005668/en/
OmniAb, Inc. Neha Singh, Ph.D. investors@omniab.com Twitter
@OmniAbTech (510) 768-7760
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni OmniAb (NASDAQ:OABI)
Storico
Da Ott 2023 a Ott 2024